Use fundamental data analysis to confirm all available drivers of ResMed to find out if markets are presently mispricing the firm. We found thirty-eight available financial ratios for ResMed which can be compared to its competitors. To make sure the equity is not overpriced, please check all ResMed fundamentals including its Revenue, Current Ratio, Market Capitalization, as well as the relationship between Cash and Equivalents and Earnings Per Share . Given that ResMed has Price to Earning of 50.61X, we recommend you check out ResMed recent market performance to make sure the company can sustain itself down the road. Use ResMed to protect your portfolios against small markets fluctuations. The stock experiences normal downward trend and little activity. Check odds of ResMed to be traded at $116.22 in 30 days.
ResMed Company Summary
ResMed competes with DENTSPLY SIRONA, Stryker, Teleflex Incorporated, and Varian Medical. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and is traded on New York Stock Exchange. It employs 6000 people.
ResMed Short Ratio vs Return On Equity
ResMed is rated below average in short ratio category among related companies. It is rated below average in return on equity category among related companies reporting about 6.17 of Return On Equity per Short Ratio.
|Short Ratio ( times )|
|Return On Equity ( % )|
ResMed Systematic Risk